Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 372

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research

Open access
Marchiò, C., Scaltriti, M., Ladanyi, M., Iafrate, A.J., Bibeau, F., Dietel, M., Hechtman, J.F., Troiani, T., López-Rios, F., Douillard, J.-Y., Andrè, F., Reis-Filho, J.S. · 2019 · Annals of Oncology

Abstract

NTRK1, NTRK2 and NTRK3 fusions have been reported in a plethora of malignancies across different histologies and represent the most common mechanism of oncogenic activation of these receptor tyrosine kinases. These fusions result in chimaeric genes, where the 3' region of NTRK is joined with a 5' sequence of a fusion partner, resulting in a constitutively activated TRK with oncogenic properties. NTRK fusions have emerged as new targets for cancer therapy as they can be successfully inhibited by small molecule kinase inhibitors leading to durable responses across disease sites. Given the multitude of partners involved in NTRK1/2/3 fusions, crucial to the administration of NTRK inhibitors is the development of optimal approaches for the detection of human cancers harbouring activating NTRK1/2/3 fusion genes. The main techniques employed for NTRK fusion gene detection include immunohistochemistry, fluorescence in situ hybridization, RT-PCR, and both RNA-based and DNA-based next-generation sequencing. Each technique has advantages and limitations, and the choice of assays for screening and final diagnosis should also take into account the resources and clinical context. The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods for the detection of NTRK gene fusions, their potential applications, and strategies for the implementation of a rational approach for the detection of NTRK1/2/3 fusion genes in human malignancies. We present here recommendations for the routine clinical detection of targetable NTRK1/2/3 fusions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdz204

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 372

Metadata

Authors
Marchiò, C., Scaltriti, M., Ladanyi, M., Iafrate, A. J., Bibeau, F., Dietel, M., Hechtman, J. F., Troiani, T., López-Rios, F., Douillard, J.-Y., Andrè, F., & Reis-Filho, J. S.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-09
Volume
30
Issue
9
Pages
1417-1427
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2953495640
Cited by
372
References
62
FWCI
35.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. https://app.cochat.ai/papers/10.1093/annonc/mdz204
The paper
Marchiò, C., Scaltriti, M., Ladanyi, M., Iafrate, A. J., Bibeau, F., Dietel, M., Hechtman, J. F., Troiani, T., López-Rios, F., Douillard, J.-Y., Andrè, F., & Reis-Filho, J. S. (2019). ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Annals of Oncology. https://doi.org/10.1093/annonc/mdz204

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.